Primary drug resistance in HIV/TB patients

V. Zimina, I. Vasilyeva, A. Kravtchenko, F. Batirov, I. Viktorova (Moscow, Novokuznetsk, Russian Federation)

Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Session: Tuberculosis in immunocompromised hosts
Session type: Poster Discussion
Number: 1937
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Zimina, I. Vasilyeva, A. Kravtchenko, F. Batirov, I. Viktorova (Moscow, Novokuznetsk, Russian Federation). Primary drug resistance in HIV/TB patients. Eur Respir J 2011; 38: Suppl. 55, 1937

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Primary drug resistance of mycobacterium tuberculosis in HIV-positive patients
Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA)
Year: 2016

Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007


Primary and acquired drug resistance in childhood tuberculosis
Source: Eur Respir J 2005; 26: Suppl. 49, 653s
Year: 2005

Burden of the primary drug resistance of Mycobacterium tuberculosis in HIV-positive patients
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019

Bedaquiline in treatment of TB/HIV co-infection patients with extremely-drug resistance of MBT
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018

MDR-TB and XDR-TB: drug resistance and treatment outcomes
Source: Eur Respir J 2009; 34: 778
Year: 2009


Primary drug resistance in HIV/tuberculosis patients in two large cities of Siberia
Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA)
Year: 2016

Primary drug resistance rates in pulmonary tuberculosis
Source: Eur Respir J 2003; 22: Suppl. 45, 42s
Year: 2003

Medico-social features of resistance development to new anti–TB drugs in patients with MDR/XDR TB
Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis
Year: 2021


Effectiveness of the intensive phase of chemotherapy in pulmonary TB patients with primary drug resistance
Source: Eur Respir J 2006; 28: Suppl. 50, 290s
Year: 2006

Predictors of death in patients with MDR-TB and HIV
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020


Prevalance of initial and acquired resistance to antituberculosis drugs in our clinic
Source: Eur Respir J 2005; 26: Suppl. 49, 653s
Year: 2005

Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline
Source: International Congress 2019 – Tuberculosis: a public health approach
Year: 2019

Primary drug resistance in pulmonary tuberculosis
Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases
Year: 2007


Antituberculosis drug resistance rates in patients newly diagnosed with TB in Istanbul
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II
Year: 2012

Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019
Year: 2020



Antituberculous drug resistance rates in soldier patients newly diagnosed with TB in Turkey
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010

Immunologic recovery in HIV/TB co-infected patients after anti-TB treatment
Source: Annual Congress 2009 - Tuberculosis and HIV co-infection
Year: 2009


The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010

First line anti-tuberculous drug resistance prevalence and its pattern among HIV infected patients in the national referral TB center, Iran
Source: Annual Congress 2009 - Tuberculosis and HIV co-infection
Year: 2009